1036730-42-3

1036730-42-3 structure

1036730-42-3 structure

Name: Pidilizumab
Chemical Name: Pidilizumab
CAS Number: 1036730-42-3
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Immunology/Inflammation PD-1/PD-L1
Create Date: 2018-06-15 03:14:46
Modify Date: 2024-02-13 15:19:59
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research[1].

Name	Pidilizumab

Description	Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1
References	[1]. Jason R Westin, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77. [2]. Aline de Oliveira Albuquerque, et al. Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1. J Biomol Struct Dyn. 2022 Sep;40(14):6450-6462.

No Any Chemical & Physical Properties